Keywords: Roche, Illumina, M&A, Options

Roche has options beyond Illumina

Article | 07 March 2012

Print This

Speaking at the company's annual meeting, Swiss drug major Roche (ROG: SIX) chairman Franz Humer said: "Our strategy of concentrating ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in